Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis
- 26 August 2023
- journal article
- research article
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 58, 73-78
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Prevention of malnutrition in cystic fibrosisCurrent Opinion in Pulmonary Medicine, 2019
- Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del AlleleNew England Journal of Medicine, 2019
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialThe Lancet, 2019
- Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosisJournal of Cystic Fibrosis, 2019
- The impact of cystic fibrosis-related diabetes on health-related quality of lifeJournal of Cystic Fibrosis, 2019
- Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating MutationsThe Journal of Pediatrics, 2018
- Abnormal Glucose Tolerance in Infants and Young Children with Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2016
- ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosisClinical Nutrition, 2016
- Better Nutritional Status in Early Childhood Is Associated with Improved Clinical Outcomes and Survival in Patients with Cystic FibrosisThe Journal of Pediatrics, 2013
- Insulin Therapy to Improve BMI in Cystic Fibrosis–Related Diabetes Without Fasting HyperglycemiaDiabetes Care, 2009